Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

BACKGROUND: Treatment options for Chinese patients with locally advanced or metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line chemotherapy are limited. This study (ORIENT‐3) aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second‐lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Wu, Lin, Yu, Xinmin, Xing, Puyuan, Wang, Yan, Zhou, Jianying, Wang, Airong, Shi, Jianhua, Hu, Yi, Wang, Ziping, An, Guangyu, Fang, Yong, Sun, Sanyuan, Zhou, Caicun, Wang, Changli, Ye, Feng, Li, Xingya, Wang, Junye, Wang, Mengzhao, Liu, Yunpeng, Zhao, Yanqiu, Yuan, Ying, Feng, Jifeng, Chen, Zhendong, Shi, Jindong, Sun, Tao, Wu, Gang, Shu, Yongqian, Guo, Qisen, Zhang, Yi, Song, Yong, Zhang, Shucai, Chen, Yuan, Li, Wei, Niu, Hongrui, Hu, Wenwei, Wang, Lijun, Huang, Jianan, Zhang, Yang, Cheng, Ying, Wu, Zhengdong, Peng, Bo, Sun, Jiya, Mancao, Christoph, Wang, Yanqi, Sun, Luyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759762/
https://www.ncbi.nlm.nih.gov/pubmed/36336841
http://dx.doi.org/10.1002/cac2.12385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759762/
https://www.ncbi.nlm.nih.gov/pubmed/36336841
http://dx.doi.org/10.1002/cac2.12385

Ejemplares similares